A number of other research analysts have also recently weighed in on the stock. Wedbush boosted their price objective on shares of Audentes Therapeutics to $56.00 and gave the company an outperform rating in a research report on Thursday, January 4th. HC Wainwright set a $37.00 price objective on shares of Audentes Therapeutics and gave the company a buy rating in a research report on Thursday, January 4th. BidaskClub upgraded shares of Audentes Therapeutics from a buy rating to a strong-buy rating in a research report on Wednesday, December 20th. BMO Capital Markets assumed coverage on shares of Audentes Therapeutics in a research report on Tuesday, December 5th. They set an outperform rating and a $35.00 price objective on the stock. Finally, ValuEngine cut shares of Audentes Therapeutics from a hold rating to a sell rating in a research report on Friday, December 1st. Two analysts have rated the stock with a sell rating, one has given a hold rating, seven have issued a buy rating and one has issued a strong buy rating to the stock. The stock has a consensus rating of Buy and an average price target of $35.00.
Audentes Therapeutics (BOLD) traded down $4.56 during trading on Friday, reaching $32.06. 653,400 shares of the company were exchanged, compared to its average volume of 879,420. The stock has a market capitalization of $957.16 and a P/E ratio of -9.21. Audentes Therapeutics has a 52 week low of $13.90 and a 52 week high of $41.80.
In other news, SVP Mary Newman sold 10,000 shares of the company’s stock in a transaction dated Thursday, November 16th. The shares were sold at an average price of $26.84, for a total value of $268,400.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, VP Suyash Prasad sold 8,000 shares of the company’s stock in a transaction dated Friday, December 1st. The stock was sold at an average price of $28.53, for a total transaction of $228,240.00. The disclosure for this sale can be found here. Insiders have sold 36,000 shares of company stock worth $1,052,480 in the last quarter. Company insiders own 47.30% of the company’s stock.
Several hedge funds and other institutional investors have recently bought and sold shares of BOLD. Schwab Charles Investment Management Inc. grew its holdings in shares of Audentes Therapeutics by 139.3% in the second quarter. Schwab Charles Investment Management Inc. now owns 25,600 shares of the biotechnology company’s stock worth $490,000 after purchasing an additional 14,900 shares during the last quarter. Rhumbline Advisers bought a new position in shares of Audentes Therapeutics in the second quarter worth about $252,000. State of Wisconsin Investment Board bought a new position in shares of Audentes Therapeutics in the second quarter worth about $210,000. Bank of New York Mellon Corp grew its holdings in shares of Audentes Therapeutics by 180.7% in the second quarter. Bank of New York Mellon Corp now owns 52,900 shares of the biotechnology company’s stock worth $1,012,000 after purchasing an additional 34,057 shares during the last quarter. Finally, Alliancebernstein L.P. grew its holdings in shares of Audentes Therapeutics by 31.5% in the second quarter. Alliancebernstein L.P. now owns 640,654 shares of the biotechnology company’s stock worth $12,256,000 after purchasing an additional 153,617 shares during the last quarter. Hedge funds and other institutional investors own 78.95% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the property of of Community Financial News. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.com-unik.info/2018/01/09/audentes-therapeutics-bold-stock-rating-reaffirmed-by-william-blair.html.
Audentes Therapeutics Company Profile
Audentes Therapeutics, Inc is an early-stage biotechnology company. The Company is focused on developing and commercializing gene therapy products for patients suffering from serious, life-threatening rare diseases caused by single gene defects. The Company has a portfolio of product candidates, including AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM); AT342 for the treatment of Crigler-Najjar Syndrome (Crigler-Najjar); AT982 for the treatment of Pompe disease, and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).
What are top analysts saying about Audentes Therapeutics? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Audentes Therapeutics and related companies.